Alpha Teknova

Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. It provides reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company was founded by Thomas E. Davis in 1996 and is headquartered in Hollister, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teknova reports mixed Q4 results, focuses on cost optimization

Teknova's Q4 2022 earnings call highlighted a mixed financial performance with revenue decline offset by full-year growth, emphasizing the importance of strategic investments and operational efficiency.
Challenges in profitability, including a net loss and negative adjusted EBITDA, underscore the need for cost management and revenue optimization strategies to drive sustainable growth.
Despite facing financial hurdles, Teknova's focus on balancing cost reduction with growth initiatives and maintaining liquidity sets the stage for future financial resilience and market competitiveness.

Teknova reports mixed Q1 2023 results, eyes growth opportunities

Teknova's Q1 2023 performance showed a mix of positive and negative indicators, with revenue growth and expense management as strengths, while challenges include declining total revenue and negative adjusted EBITDA. The company's focus on innovation, cost control, and market research presents opportunities for future growth and margin improvement.

TEKNOVA reports robust Q2 revenue growth amidst operational optimizations

TEKNOVA's Q2 2023 showed strong revenue growth and operational improvements.
Despite challenges, the company remains optimistic about its future growth prospects.
Strategic investments in R&D and manufacturing capabilities position TEKNOVA for long-term success.
Efforts to manage expenses and achieve free cash flow targets are key priorities.

Alpha Teknova reports Q3 revenue decline, focuses on financial stability

Alpha Teknova (TKNO) faced revenue declines in Q3 2023, with a net loss of $10.2 million and negative adjusted EBITDA of $5.5 million.
Despite challenges, the company strengthened its financial position through a direct offering, debt repayment, and cost reduction initiatives.
Teknova's focus on managing costs, cash outflows, and strategic investments underscores its commitment to financial stability and operational efficiency.
While facing performance headwinds, Teknova aims to navigate challenges and leverage opportunities for sustainable growth and improved profitability.

Teknova maintains stability, eyes growth through cost savings and partnerships

Teknova's Q4 2023 performance showed stability in revenue and operational improvements, with a focus on cost-saving initiatives and revenue guidance for 2024.
Despite challenges in Clinical Solutions and margin pressures, Teknova's strong customer service, cost reductions, and market opportunities position it for growth.
Strategic partnerships, industry-leading Net Promoter Scores, and a positive outlook on cell and gene therapy approvals present avenues for revenue enhancement and market expansion.

Alpha Teknova (TKNO) reports solid Q1 performance amidst profitability challenges

Alpha Teknova (TKNO) delivered a strong performance in Q1 2024, showcasing revenue growth, cost management success, and operational highlights.
While facing challenges with negative adjusted EBITDA and maintaining gross margin, Teknova's strengths lie in expense management, innovation, and market positioning.
Opportunities for Teknova include product launches, market stabilization, and customer base expansion, setting the stage for future growth and success.
To sustain growth, Teknova must address profitability challenges, balance expense management with revenue growth, and capitalize on market opportunities.

Alpha Teknova (TKNO) reports Q2 growth, eyes profitability without funding

Alpha Teknova (TKNO) showed improved sequential revenue and EBITDA performance in Q2 2024. The company introduced new high-margin offerings and closed a capital raise to drive profitability. Challenges include YoY revenue decline and the need for market stabilization.

Alpha Teknova (TKNO) reports robust Q3 results and outlines growth strategies

Alpha Teknova's Q3 2024 earnings call highlighted strong financial performance, growth in key segments, and ongoing efforts to enhance profitability. While facing challenges in certain revenue streams, the company remains optimistic about its outlook and strategic initiatives for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOLLISTER, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced registered direct offering for the issuance and sale of an aggregate of 1,086,485 of its shares of common stock at a purchase price of $1.85 per share and concurrent private placement of an aggregate of 11,299,993 of its shares of common stock, at the same purchase price of $1.85 per share. The registered direct offering and the private placement were priced based on the consolidated closing bid price under Nasdaq rules.

Teknova Announces Closing of $22.9 Million Concurrent Registered Direct Offering and Private Placement and Amends Credit Facility

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Sara Michelmore - MacDougall Advisors Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Steven Mah - TD Cowen Matt Larew - William. Blair Paul Knight - KeyBanc Mark Massaro - BTIG Jacob Johnson - Stephens Operator Good day, and welcome to Teknova's Second Quarter 2023 Financial Results Conference Call.

Alpha Teknova, Inc. (TKNO) Q2 2023 Earnings Call Transcript

Second quarter 2023 total revenue was $11.5 million, up 26% sequentially Received certification of new state-of-the-art facility for production of GMP-grade products Company revises 2023 revenue guidance to $37-40 million, continues to anticipate free cash outflows of $30 million for full year

Teknova Reports Second Quarter 2023 Financial Results

State-of-the-art facility in Hollister, California is designed to help bioprocessing and gene therapy companies scale from research to clinical production State-of-the-art facility in Hollister, California is designed to help bioprocessing and gene therapy companies scale from research to clinical production

Teknova Announces Opening of New GMP-Certified Facility, Increasing Manufacturing Capacity for Custom, High-Quality Life Sciences Reagents

HOLLISTER, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, following the close of market.

Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023

First-of-its-kind screening kit now available for AAV8 – along with a suite of high-quality reagents to support the entire AAV workflow – helping gene therapy developers save months in process development First-of-its-kind screening kit now available for AAV8 – along with a suite of high-quality reagents to support the entire AAV workflow – helping gene therapy developers save months in process development

Teknova Expands Proprietary AAV-Tek™ Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development

HOLLISTER, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will present and host individual and small group meetings at the following upcoming investor conference:

Teknova to Participate in Upcoming Investor Conference

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2023 Earnings Conference Call May 10, 2023 5:30 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Madeline Mollman - William Blair Steven Mah - TD Cowen Operator Good day, and welcome to the Teknova First Quarter 2023 Financial Results Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Alpha Teknova, Inc. (TKNO) Q1 2023 Earnings Call Transcript

First quarter 2023 total revenue was $9.1 million, up 16% sequentially Launch of proprietary AAV-Tek™  Solutions gene therapy product line Company reaffirms 2023 revenue guidance of $42-46 million HOLLISTER, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2023.

Teknova Reports First Quarter 2023 Financial Results

Company will share their latest findings for custom product innovations aimed at addressing key gene therapy bioprocessing bottlenecks Company will share their latest findings for custom product innovations aimed at addressing key gene therapy bioprocessing bottlenecks

Teknova to Present Data on Novel Products to Accelerate the Development of AAV Therapies at ASGCT 2023 Annual Meeting

Alpha Teknova (TKNO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Alpha Teknova (TKNO) a New Strong Buy Stock

HOLLISTER, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, following the close of market.

Teknova to Report First Quarter 2023 Financial Results on May 10, 2023

Alpha Teknova (TKNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Alpha Teknova (TKNO) Loses -29.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Down -48.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Alpha Teknova (TKNO)

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q4 2022 Results Conference Call March 15, 2023 5:00 PM ET Company Participants Jen Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Joseph Flanagan - Cowen Matt Larew - William Blair Hannah Hefley - Stephens Operator Thank you for standing by, and welcome to Teknova's Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode.

Alpha Teknova, Inc. (TKNO) Q4 2022 Earnings Call Transcript

Full year 2022 total revenue was $41.4 million, up 12% year-over-year New, state-of-the-art manufacturing facility now operational Company provides 2023 revenue guidance of $42-46 million

Teknova Reports Fourth Quarter and Full Year 2022 Financial Results

An AAV chromatography platform plus optimized custom buffer formulations yields a state-of-the-art offering for increased AAV recovery An AAV chromatography platform plus optimized custom buffer formulations yields a state-of-the-art offering for increased AAV recovery

Teknova and Sartorius BIA Separations Announce Collaboration to Address Critical Pain Point in Gene Therapy Process Development

AdaptHealth Corp

Cara Therapeutics

Infinity Pharma

OptimizeRx Corp

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)

HOLLISTER, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conferences:

Teknova to Participate in Upcoming Investor Conferences

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q3 2022 Earnings Conference Call November 21, 2022 4:30 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Teknova Third Quarter 2022 Financial Results Conference Call.

Alpha Teknova, Inc. (TKNO) Q3 2022 Earnings Call Transcript

Third quarter 2022 total revenue was $10.7 million, up 14% year-over-year Company updates 2022 revenue outlook to $40-42 million Cash position of $50 million supports path to profitability

Teknova Reports Third Quarter 2022 Financial Results

HOLLISTER, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2022, on Wednesday, November 9, 2022, following the close of market.

Teknova to Report Third Quarter 2022 Financial Results on November 9, 2022

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Sara Michelmore - Head of Investor Relations, MacDougall Advisors Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Stephanie Yan - Cowen Matt Larew - William Blair Jake Johnson - Stephens Operator Good day, and thank you for standing by. Welcome to the Teknova Second Quarter 2022 Financial Results Conference Call.

Alpha Teknova, Inc. (TKNO) CEO Stephen Gunstream on Q2 2022 Results - Earnings Call Transcript

Second quarter 2022 total revenue was $11.7 million, up 41% year-over-year Cash position of $64.7 million supports ongoing investment in growth strategy Company updates 2022 revenue outlook to $38-42 million

Teknova Reports Second Quarter 2022 Financial Results

HOLLISTER, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2022, on Wednesday, August 10, 2022, following the close of market.

News for Alpha Teknova Stock (TKNO)